CDK6 and adrenal cortex carcinoma: As shown in Figure 5, survival analysis for ACC showed that the high expression of CDK6 led to a poor prognosis for patients (HR = 1.77, p <.001), and the area under the curve (AUC) at 1, 3, and 5 years was greater than 0.7, indicating that the expression of CDK6 can be confidently used to predict adverse survival outcomes of ACC patients.